Skip to content

    Osteoporosis Health Center

    Select An Article

    Selective Estrogen Receptor Modulators (SERMs)

    Font Size
    A
    A
    A

    Raloxifene (Evista)

    Raloxifene (Evista) belongs to a class of drugs called selective estrogen receptor modulators (SERMs). It is FDA-approved for the prevention and treatment of osteoporosis in postmenopausal women.

    SERMs were developed to reap the benefits of estrogen while avoiding the hormone's potential side effects. Raloxifene, a so-called ''designer'' estrogen, can act like estrogen on bone -- protecting its density -- but as an anti-estrogen on the lining of the uterus.

    Recommended Related to Osteoporosis

    Osteoporosis and Diet: Recipes for Strong Bones

    When you've been diagnosed with osteoporosis you want a diet with a steady supply of bone-building nutrients. The delicious dishes that follow offer a bevy of calcium and vitamin D, which form the foundation of a diet for a sturdy skeleton, as well as other nutrients critical for bone health, including protein. An added bonus: The salmon chowder is especially rich in omega-3 fats, beneficial to your bones and your heart, and supplies nearly all the vitamin D most adults 19 to 50 years old need for...

    Read the Osteoporosis and Diet: Recipes for Strong Bones article > >

    In a three-year study involving some 600 postmenopausal women, raloxifene was found to increase bone density and lower LDL cholesterol, while having no stimulative effect on the uterine lining (which means that it is unlikely to cause uterine cancer).

    The first SERM to reach the market was tamoxifen, which blocks the stimulative effect of estrogen on breast tissue. Tamoxifen has proven valuable in preventing cancer in the second breast of women who have had cancer in one breast.

    Because of its anti-estrogen effects, the most common side effects with raloxifene are hot flashes. Conversely, because of its estrogenic effects, raloxifene increases the risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (blood clots in the lung). The greatest increase in risk occurs during the first four months of use. Patients taking raloxifene should avoid tobacco use and prolonged periods of immobility during travel, when blood clots are more prone to occur. The risk of deep vein thrombosis with raloxifene is probably comparable to that of estrogen, about 2 to 3 times higher than the usual low occurrence rate.

    Raloxifene decreases the risk of spine fractures in postmenopausal women with osteoporosis, but the benefit in decreasing hip fracture risk is not yet known. (The only agents that are definitely proven to decrease hip fracture risk are bisphosphonates.)

    Another SERM, Duavee (bazedoxifene-conjugated estrogen), is FDA-approved to reduce hot flashes and osteoporosis in postmenopausal women.

    WebMD Medical Reference

    Reviewed by Trina Pagano, MD on November 01, 2014
    Next Article:

    Today on WebMD

    Women working out and walking with weights
    Reduce bone loss and build stronger muscles.
    Chinese cabbage
    Calcium-rich foods to add to your diet.
     
    woman stretching
    Get the facts on osteoporosis.
    Porous bone
    Causes, symptoms, risk factors, and treatment.
     
    senior woman
    Article
    Woman holding plate of brocolli
    Article
     
    wrist xray
    Quiz
    Superfood for Bones
    Slideshow
     
    mature woman
    Article
    sunlight in hands
    Article
     
    man and woman in front of xray
    Quiz
    woman with dumbbells
    Article